Please login to the form below

Not currently logged in
Email:
Password:

Johnson & Johnson buys $1bn Elan stake

J&J will invest $1bn (£600m) in Elan and commit $500m to help fund development of the company's late-stage products for Alzheimer's

Johnson & Johnson(J&J) will invest $1bn (£600m) in the Irish-American company Elan and commit an additional $500m to help fund development of the company's late-stage products for Alzheimer's disease.

In return, the US healthcare products group will acquire an 18.4 per cent stake in the company and assume majority control of its two leading experimental Alzheimer's products, which are being developed in partnership with US giant Wyeth.

The deal ends months of uncertainty over Elan's financial stability and marks a vote of confidence in the development of a late-stage drug and vaccine for Alzheimer's which had been thrown into question by Pfizer's takeover of Wyeth.

Elan will hold a 49.9 per cent stake in the newly formed company. It will be entitled to a 49.9 per cent share of the profits and certain royalty payments if products developed under the Wyeth partnership reach market.  

Sheri McCoy, J&J worldwide chairman of pharmaceuticals said: "Alzheimer's disease is a significant unmet need in ageing populations globally. J&J's development capabilities, commercial experience and global reach will provide the foundation to accelerate the (Alzheimer's programme) and increase its potential for patients globally."

Shares in Elan have risen 40 per cent on the news. The deal is expected to close in the second half of the year.

6th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics